New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 30, 2014
07:54 EDTAGN, VRXValeant Allergan battle likely to continue for some time, says Bernstein
Bernstein believes that the struggle between Valeant (VRX) and Allergan (AGN) will become "a trench battle," and will likely last until the end of the year. The firm thinks that both sides will continue to try to create value for Allergan shareholders in the near-term. Bernstein keeps a $190 price target and Outperform rating on Allergan.
News For VRX;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2015
09:18 EDTVRXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use